Novigenix
Novigenix is a Swiss molecular diagnostics company focused on innovative blood tests for early cancer detection. Their flagship product, Colox®, is a proven molecular blood test designed to reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. The company's technology is based on predictive gene expression profiles of circulating blood cells and tumor-derived protein markers, combined with advanced mathematical models, providing accurate solutions for early cancer detection. Novigenix aims to increase the availability of Colox in Switzerland and Europe through partnerships and is actively involved in raising awareness about colorectal cancer prevention and screening.
Industries
Nr. of Employees
small (1-50)
Novigenix
Capricorn One, Lausanne, Switzerland
Patents
Products
Blood-based molecular diagnostic test for colorectal cancer
A diagnostic test and kit format that measures a host immune-response multigene signature together with plasma tumor-protein markers to identify patients with advanced adenomas and early colorectal cancer for referral to diagnostic follow-up.
Blood-based molecular diagnostic test for colorectal cancer
A diagnostic test and kit format that measures a host immune-response multigene signature together with plasma tumor-protein markers to identify patients with advanced adenomas and early colorectal cancer for referral to diagnostic follow-up.
Services
Provision of blood-based molecular testing services that combine host immune-response gene-expression profiling with plasma tumor-protein measurements for case-finding and screening support, delivered through clinical laboratory workflows.
Analytical and translational support combining immune-transcriptomic profiling and molecular biomarker analysis to inform clinical development, mechanism-of-action studies, and cohort analysis.
Collaborative development of predictive models that integrate immune transcriptomics with tumor-derived and clinical data to predict therapy response and potential toxicity biomarkers.
Provision of blood-based molecular testing services that combine host immune-response gene-expression profiling with plasma tumor-protein measurements for case-finding and screening support, delivered through clinical laboratory workflows.
Analytical and translational support combining immune-transcriptomic profiling and molecular biomarker analysis to inform clinical development, mechanism-of-action studies, and cohort analysis.
Collaborative development of predictive models that integrate immune transcriptomics with tumor-derived and clinical data to predict therapy response and potential toxicity biomarkers.
Expertise Areas
- Blood-based immune-response profiling
- Biomarker discovery and multi-omics integration
- Early cancer-detection diagnostics
- Clinical study design and multicenter validation
Key Technologies
- Whole-blood and PBMC RNA stabilization
- Multigene expression profiling (qPCR/targeted panels)
- Plasma tumor-protein biomarker assays
- Next-generation sequencing
News & Updates
Novigenix announced the acquisition of Colox®, a molecular blood test for colorectal cancer detection, and plans to expand its availability in Switzerland and Europe through partnerships. The test has been approved for sale in Europe and launched in Switzerland.
Novigenix announced a commercialization agreement with Dr Risch Medical Laboratory, a leading Swiss clinical laboratory, to distribute Colox® in the Swiss German market and Liechtenstein. The partnership aims to support early detection of colorectal cancer and reduce mortality.
Novigenix announced the acquisition of Colox®, a molecular blood test for colorectal cancer detection, and plans to expand its availability in Switzerland and Europe through partnerships. The test has been approved for sale in Europe and launched in Switzerland.
Novigenix announced a commercialization agreement with Dr Risch Medical Laboratory, a leading Swiss clinical laboratory, to distribute Colox® in the Swiss German market and Liechtenstein. The partnership aims to support early detection of colorectal cancer and reduce mortality.